Tularemia is a disease of animals and humans caused by the bacterium Francisella tularensis. Rabbits, hares, and rodents are especially susceptible and often die in large numbers during outbreaks. Humans can become infected through several routes, including tick and deer fly bites, skin contact with infected animals, ingestion of contaminated water, or inhalation of contaminated dusts or aerosols. In addition, humans could be exposed as a result of bioterrorism. Symptoms vary depending upon the route of infection. Although tularemia can be life-threatening, most infections can be treated successfully with antibiotics. Steps to prevent tularemia include use of insect repellent, wearing gloves when handling sick or dead animals, and not mowing over dead animals. In the United States, naturally occurring infections have been reported from all States except Hawaii.
Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.
Immunologists at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC and the have found a unique quirk in the way the immune system fends off bacteria called Francisella tularensis, which could lead to vaccines that are better able to prevent tularemia infection of the lungs. Their findings were published today in the early, online version of Immunity.
In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.
Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).
Researchers are closer to developing therapies to combat the deadly tularemia infection, according to a study published this week in the Proceedings of the National Academy of Sciences' online Early Edition.
Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick.
In the event of an outbreak or a bioterrorist attack, rapid identification of the genetic changes responsible for virulence or drug resistance is essential to mounting an effective response.
Researchers at MIT Lincoln Laboratory have developed a powerful sensor that can detect airborne pathogens such as anthrax and smallpox in less than three minutes.
A purified extract prepared from a common microbe and delivered to the lungs of laboratory mice in a spray set off a healthy immune response and provided powerful protection against all four major classes of pathogens including those responsible for anthrax and bubonic plague, according to a presentation at the American Society for Cell Biology's 47th Annual Meeting.
An inhaled immune system stimulant protects mice against lethal pneumococcal pneumonia and other deadly bacterial, viral and fungal infections of the lungs, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at a major scientific meeting.
The respiratory form of tularemia, a potentially serious bacterial disease, is a significant public health concern because it is highly infectious, it has a high mortality rate if untreated, and it could be introduced into a population in an intentional act of bioterror.
It's the most common bacteria-related sexually transmitted disease in the United States, so researchers at The University of Texas at San Antonio's South Texas Center for Emerging Infectious Diseases (STCEID) and The University of Texas at San Antonio Health Science Center have partnered to discover a vaccine that will prevent Chlamydia.
A new program at the National Institute of Allergy and Infectious Diseases (NIAID) aims to better understand the complex biochemical networks that regulate the interactions between infectious organisms and the human or animal cells they infect.
When bacterial pathogens attack the surface of a cell, vaccine-induced antibodies can mount a formidable defense and fend off the bad bugs.
A new study found that an extremely infectious pneumonia-like disease in humans slips through the immune system's usual defense mechanisms.
A supermarket checkout computer can identify thousands of different items by scanning the tiny barcode printed on the package. New technology developed at Cornell University could make it just as easy to identify genes, pathogens, illegal drugs and other chemicals of interest by tagging them with color-coded probes made out of synthetic tree-shaped DNA.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.